An update on SARS-CoV-2 immunization and future directions
Millions of people have died as a result of SARS-CoV-2, which was first discovered in China and has since spread globally. Patients with SARS-CoV-2 infection may show a range of symptoms, including fever, coughing, and shortness of breath, or they may show no symptoms at all. To treat COVID-19 sympt...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-03-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2023.1125305/full |
| _version_ | 1827996553041674240 |
|---|---|
| author | Rashmi Rana Ravi Kant Tanya Kumra Sneha Gupta Devinder Singh Rana Nirmal Kumar Ganguly |
| author_facet | Rashmi Rana Ravi Kant Tanya Kumra Sneha Gupta Devinder Singh Rana Nirmal Kumar Ganguly |
| author_sort | Rashmi Rana |
| collection | DOAJ |
| description | Millions of people have died as a result of SARS-CoV-2, which was first discovered in China and has since spread globally. Patients with SARS-CoV-2 infection may show a range of symptoms, including fever, coughing, and shortness of breath, or they may show no symptoms at all. To treat COVID-19 symptoms and avoid serious infections, many medications and vaccinations have been employed. However, to entirely eradicate COVID-19 from the world, next-generation vaccine research is required because of the devastating consequences it is having for humanity and every nation’s economy. Scientists are working hard to eradicate this dangerous virus across the world. SARS-CoV-2 has also undergone significant mutation, leading to distinct viral types such as the alpha, beta, gamma, delta, and omicron variants. This has sparked discussion about the effectiveness of current vaccines for the newly formed variants. A proper comparison of these vaccinations is required to compare their efficacy as the number of people immunized against SARS-CoV-2 globally increases. Population-level statistics evaluating the capacity of these vaccines to reduce infection are therefore being developed. In this paper, we analyze the many vaccines on the market in terms of their production process, price, dosage needed, and efficacy. This article also discusses the challenges of achieving herd immunity, the likelihood of reinfection, and the importance of convalescent plasma therapy in reducing infection. |
| first_indexed | 2024-04-10T05:13:44Z |
| format | Article |
| id | doaj.art-5e139036313b408da0b51762f3e745fd |
| institution | Directory Open Access Journal |
| issn | 1663-9812 |
| language | English |
| last_indexed | 2024-04-10T05:13:44Z |
| publishDate | 2023-03-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Pharmacology |
| spelling | doaj.art-5e139036313b408da0b51762f3e745fd2023-03-09T05:07:27ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122023-03-011410.3389/fphar.2023.11253051125305An update on SARS-CoV-2 immunization and future directionsRashmi Rana0Ravi Kant1Tanya Kumra2Sneha Gupta3Devinder Singh Rana4Nirmal Kumar Ganguly5Department of Research, Sir Ganga Ram Hospital, New Delhi, IndiaDepartment of Research, Sir Ganga Ram Hospital, New Delhi, IndiaDepartment of Research, Sir Ganga Ram Hospital, New Delhi, IndiaDepartment of Research, Sir Ganga Ram Hospital, New Delhi, IndiaDepartment of Nephrology, Sir Ganga Ram Hospital, New Delhi, IndiaDepartment of Research, Sir Ganga Ram Hospital, New Delhi, IndiaMillions of people have died as a result of SARS-CoV-2, which was first discovered in China and has since spread globally. Patients with SARS-CoV-2 infection may show a range of symptoms, including fever, coughing, and shortness of breath, or they may show no symptoms at all. To treat COVID-19 symptoms and avoid serious infections, many medications and vaccinations have been employed. However, to entirely eradicate COVID-19 from the world, next-generation vaccine research is required because of the devastating consequences it is having for humanity and every nation’s economy. Scientists are working hard to eradicate this dangerous virus across the world. SARS-CoV-2 has also undergone significant mutation, leading to distinct viral types such as the alpha, beta, gamma, delta, and omicron variants. This has sparked discussion about the effectiveness of current vaccines for the newly formed variants. A proper comparison of these vaccinations is required to compare their efficacy as the number of people immunized against SARS-CoV-2 globally increases. Population-level statistics evaluating the capacity of these vaccines to reduce infection are therefore being developed. In this paper, we analyze the many vaccines on the market in terms of their production process, price, dosage needed, and efficacy. This article also discusses the challenges of achieving herd immunity, the likelihood of reinfection, and the importance of convalescent plasma therapy in reducing infection.https://www.frontiersin.org/articles/10.3389/fphar.2023.1125305/fullCOVID-19SARS-CoV-2vaccine efficacyherd immunityreinfectionconvalescent plasma therapy |
| spellingShingle | Rashmi Rana Ravi Kant Tanya Kumra Sneha Gupta Devinder Singh Rana Nirmal Kumar Ganguly An update on SARS-CoV-2 immunization and future directions Frontiers in Pharmacology COVID-19 SARS-CoV-2 vaccine efficacy herd immunity reinfection convalescent plasma therapy |
| title | An update on SARS-CoV-2 immunization and future directions |
| title_full | An update on SARS-CoV-2 immunization and future directions |
| title_fullStr | An update on SARS-CoV-2 immunization and future directions |
| title_full_unstemmed | An update on SARS-CoV-2 immunization and future directions |
| title_short | An update on SARS-CoV-2 immunization and future directions |
| title_sort | update on sars cov 2 immunization and future directions |
| topic | COVID-19 SARS-CoV-2 vaccine efficacy herd immunity reinfection convalescent plasma therapy |
| url | https://www.frontiersin.org/articles/10.3389/fphar.2023.1125305/full |
| work_keys_str_mv | AT rashmirana anupdateonsarscov2immunizationandfuturedirections AT ravikant anupdateonsarscov2immunizationandfuturedirections AT tanyakumra anupdateonsarscov2immunizationandfuturedirections AT snehagupta anupdateonsarscov2immunizationandfuturedirections AT devindersinghrana anupdateonsarscov2immunizationandfuturedirections AT nirmalkumarganguly anupdateonsarscov2immunizationandfuturedirections AT rashmirana updateonsarscov2immunizationandfuturedirections AT ravikant updateonsarscov2immunizationandfuturedirections AT tanyakumra updateonsarscov2immunizationandfuturedirections AT snehagupta updateonsarscov2immunizationandfuturedirections AT devindersinghrana updateonsarscov2immunizationandfuturedirections AT nirmalkumarganguly updateonsarscov2immunizationandfuturedirections |